{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:29:42Z","timestamp":1787167782077,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejca.2024.114188","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T11:58:18Z","timestamp":1719662298000},"page":"114188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The challenge of running trials in advanced angiosarcoma: A systematic review of the literature from EORTC\/STBSG to guide the development of angiosarcoma-specific trials"],"prefix":"10.1016","volume":"207","author":[{"given":"Armelle","family":"Dufresne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Striefler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winan","family":"Van Houdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Litiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Marreaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Stacchiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2024.114188_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246958","article-title":"Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network","volume":"16","author":"de Pinieux","year":"2021","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.ejca.2024.114188_bib2","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.114188_bib3","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1002\/cam4.1698","article-title":"Radiation-associated sarcoma after breast cancer in a nationwide population: increasing risk of angiosarcoma","volume":"7","author":"Salminen","year":"2018","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.ejca.2024.114188_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000787","article-title":"Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study","volume":"5","author":"Constantinidou","year":"2020","journal-title":"ESMO Open"},{"issue":"18","key":"10.1016\/j.ejca.2024.114188_bib5","first-page":"3178","article-title":"First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials","volume":"50","author":"Young","year":"2014","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"32","key":"10.1016\/j.ejca.2024.114188_bib6","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study","volume":"26","author":"Penel","year":"2008","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"25","key":"10.1016\/j.ejca.2024.114188_bib7","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2015.60.8505","article-title":"Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized Phase II trial","volume":"33","author":"Ray-Coquard","year":"2015","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2024.114188_bib8","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II study of sorafenib in patients with metastatic or recurrent sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114188_bib9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1634\/theoncologist.2011-0237","article-title":"Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma group (GSF\/GETO)","volume":"17","author":"Ray-Coquard","year":"2012","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ejca.2024.114188_bib10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamaoncol.2021.3547","article-title":"Efficacy and safety of TRC105 plus pazopanib vs pazopanib alone for treatment of patients with advanced angiosarcoma: a randomized clinical trial","volume":"8","author":"Jones","year":"2022","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2024.114188_bib11","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/cncr.26599","article-title":"Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas","volume":"118","author":"Italiano","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.114188_bib12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mdr066","article-title":"Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network","volume":"23","author":"Stacchiotti","year":"2012","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.114188_bib13","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/cam4.5147","article-title":"Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: a multicenter, retrospective study","volume":"12","author":"Watson","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.ejca.2024.114188_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","article-title":"Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis","volume":"56","author":"Koll\u00e1r","year":"2017","journal-title":"Acta Oncol Stock Swed"},{"issue":"8","key":"10.1016\/j.ejca.2024.114188_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"18","key":"10.1016\/j.ejca.2024.114188_bib16","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1002\/cncr.34370","article-title":"Clinical activity of checkpoint inhibitors in angiosarcoma: a retrospective cohort study","volume":"128","author":"Ravi","year":"2022","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2024.114188_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004149","article-title":"Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center","volume":"10","author":"Rosenbaum","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.114188_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","article-title":"Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution","volume":"7","author":"Florou","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2024.114188_bib19","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2024.114188_bib20","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1158\/1078-0432.CCR-22-3911","article-title":"A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma","volume":"29","author":"Kelly","year":"2023","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2024.114188_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","article-title":"The angiosarcoma project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research","volume":"26","author":"Painter","year":"2020","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.ejca.2024.114188_bib22","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.3390\/cancers13194816","article-title":"Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis","volume":"13","author":"Espejo-Freire","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.ejca.2024.114188_bib23","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1172\/JCI139080","article-title":"Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma","volume":"130","author":"Chan","year":"2020","journal-title":"J Clin Invest"},{"issue":"23","key":"10.1016\/j.ejca.2024.114188_bib24","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.3390\/cancers14235938","article-title":"Immunological and genomic analysis reveals clinically relevant distinctions between angiosarcoma subgroups","volume":"14","author":"van Ravensteijn","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ejca.2024.114188_bib25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s12026-021-09259-4","article-title":"Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups","volume":"70","author":"Tomassen","year":"2022","journal-title":"Immunol Res"},{"issue":"6","key":"10.1016\/j.ejca.2024.114188_bib26","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41591-022-01821-3","article-title":"Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort","volume":"28","author":"Italiano","year":"2022","journal-title":"Nat Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492400844X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492400844X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:21:29Z","timestamp":1786969289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492400844X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":26,"alternative-id":["S095980492400844X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114188","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The challenge of running trials in advanced angiosarcoma: A systematic review of the literature from EORTC\/STBSG to guide the development of angiosarcoma-specific trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114188","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114188"}}